A Study of CHM-029 in Participants With NPM1 Mutated, KMT2A or NUP98 Rearranged AML

NCT07751991 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

40

Enrollment

INDUSTRY

Sponsor class

Conditions

AML (Acute Myeloid Leukemia)

Interventions

DRUG: CHM-029

Sponsor

Charm Therapeutics